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Plasmodium falciparum: multifaceted 
resistance to artemisinins
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Abstract 
Plasmodium falciparum resistance to artemisinins, the most potent and fastest acting anti‑malarials, threatens malaria 
elimination strategies. Artemisinin resistance is due to mutation of the PfK13 propeller domain and involves an uncon‑
ventional mechanism based on a quiescence state leading to parasite recrudescence as soon as drug pressure is 
removed. The enhanced P. falciparum quiescence capacity of artemisinin‑resistant parasites results from an increased 
ability to manage oxidative damage and an altered cell cycle gene regulation within a complex network involving 
the unfolded protein response, the PI3K/PI3P/AKT pathway, the PfPK4/eIF2α cascade and yet unidentified transcrip‑
tion factor(s), with minimal energetic requirements and fatty acid metabolism maintained in the mitochondrion and 
apicoplast. The detailed study of these mechanisms offers a way forward for identifying future intervention targets to 
fend off established artemisinin resistance.
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Background
Artemisinin (ART) and its derivatives, introduced in 
1980s, are the most potent and fastest acting anti-malar-
ials, producing rapid clearance of parasitaemia and rapid 
resolution of symptoms. The discovery of artemisinin 
by Professor Youyou Tu has been rewarded the Nobel 
Prize for Physiology or Medicine 2015, recognizing that 
it has radically improved treatment against malaria [1]. 
Plasmodium falciparum artemisinin resistance was first 
detected in 2006 [2], after decreased clearance rates were 
observed in patients receiving an artemisinin therapy in 
clinical studies performed in 2006. It is nowadays wide-
spread across southeast Asia [2, 3]. The delayed clear-
ance of artemisinin-resistant infections exposes larger 
numbers of parasites to anti-malarial drugs, poten-
tially driving selection to higher-grade artemisinin or 
to the partner drug. In Asia, treatment failures of arte-
misinin-based combination therapy (ACT) have recently 
emerged, including resistance to piperaquine [4]. This 
represents a serious threat for malaria eradication, wide-
spread artemisinin resistance being predicted to cause 
in excess of 116,000 deaths annually, with medical costs 
and productivity losses evaluated as 146 million US$ and 
385 million US$ per year, respectively [5]. The resistance 
to artemisinins is due to mutation of the PfK13 propeller 
domain endowing the parasites with an increased ability 
to enter a quiescent state. Piecemeal evidence associates 
artemisinin resistance with increased unfolded protein 
response (UPR), dysregulation of the pre-replication 
phase and the PI3K/PI3P/AKT pathway. Yet, an over-
all picture about how these modifications result in qui-
escence-associated artemisinin resistance is lacking. A 
conceptual framework for the cellular networks involved 
from oxidative stress to quiescence and parasite sur-
vival is proposed here, opening novel avenues for future 
research.
Rapid overview of antiplasmodial drugs
Currently used anti-malarials belong to different chemi-
cal series and all Plasmodium falciparum stages can be 
targeted (asexual red blood cell stages, gametocytes, 
hepatic stages) by one or another anti-malarial. Each 
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antiplasmodial drug series has its own specific mode(s) 
of action. In the food vacuole, haemozoin synthesis, cor-
responding to detoxification of the waste from haemo-
globin by the parasite, is specially affected by quinolines 
[6] and artemisinins. Artemisinin and its derivatives 
are also responsible for alkylation of proteins and haem 
leading to oxidative damages [7]. At the mitochondrial 
level, atovaquone, targeting the cytochrome bc1 complex, 
inhibits the parasite electron transport chain and thus 
the dihydro-orotate dehydrogenase (DHODH) activity 
linked to the respiratory chain and involved in pyrimi-
dine nucleotide biosynthesis [8]. In the cytosol, inhibi-
tion of dihydrofolate reductase (DHFR) by proguanil or 
pyrimethamine or of dihydropteroate synthase (DHPS) 
by sulfadoxine [9], blocks the biosynthesis of folate 
involved in DNA and RNA synthesis. Unfortunately, 
most anti-malarial drugs have lost their efficacy as resist-
ance has emerged and spread.
The World Health Organization (WHO) defines resist-
ance to anti-malarials as “the ability of Plasmodium to 
survive and/or multiply despite the administration and 
absorption of a medicine given in doses equal to -or 
higher than- those usually recommended but within the 
tolerance of the subject”, with the subsequent statement 
that “the form of the drug active against the parasite 
must be able to gain access to the parasite or the infected 
red blood cell for the duration of the time necessary for 
its normal action” [10]. For some anti-malarial drugs, 
resistance occurred very quickly after their introduction 
(Table 1).
Among all mechanisms of resistance described in vari-
ous organisms, from bacteria, parasites, fungi to human 
cancer cells, two main mechanisms drive Plasmodium 
resistance to almost all anti-malarial drugs: (i) reduced 
drug availability at its site of action, essentially due to 
mutations in transporter genes; and, (ii) modification 
of the drug target by mutations in corresponding genes 
(Table  1). Artemisinin resistance results from a differ-
ent cellular process, quiescence, which is detailed below. 
The quiescence-based cellular mechanisms comply with 
the WHO definition of P. falciparum drug resistance [10] 
(see also WHO global report on drug resistance 2010), as 
artemisinin-resistant parasites survival exposure to ther-
apeutic, lethal concentrations of artemisinin derivatives.
Recommendations for the use of dual and triple therapy
Parasite resistance to drug monotherapy prompted the 
WHO to recommend dual or triple therapy, which com-
bines molecules with independent modes of action or 
distinct target enzymes. Drug combination is usually 
more effective and in the event of resistance to one com-
ponent, the second one kills residual resistant parasites. 
However, some combination therapy, such as sulfadox-
ine-pyrimethamine plus chloroquine or amodiaquine, 
must be avoided due to the high levels of resistance estab-
lished to these drugs already extensively used in mono-
therapy. For the same reason and because of the rapid 
acquisition of atovaquone resistance, atovaquone-pro-
guanil is not recommended [2, 11, 12]. Clinical resistance 
to artemisinin was first detected in Cambodia in 2006 
and reported in 2008 [13]. In 2009, Noedl et al. reported 
artemisinin resistance of uncomplicated falciparum 
malaria cases in Thailand and Cambodia and correlated 
delayed clearance with increased in vitro artemisinin IC50 
values compared to the artemisinin-sensitive clone W2 
[14]. Dondorp et  al. [15] documented reduced in  vivo 
susceptibility to artesunate in Pailin (western Cambo-
dia) compared to Wang Pha (northwestern Thailand), 
Table 1 Date of  introduction and  first reports of  anti-malarial drug resistance, resistance genes involved [33, 86, 87] 
and main mechanisms of resistance




Main resistance mechanisms Refs
Quinine 1632 1910 Pfmdr1/other Disruption of drug accumulation inside the food vacuole 
by reduced propensity of the drug transporter PfMDR1 
to bind to and transfer the anti‑malarial
[88, 89]
Chloroquine 1945 1957 Pfcrt/Pfmdr1 Drug extrusion on from digestive vacuole by mutated 
drug transporter PfCRT due to higher lipophilicity 
and negativity of the transporter allowing ionized 
chloroquine efflux
[90–92]
Proguanil 1948 1949 Pfdhfr Modification of the drug target: reduced inhibition of 
enzymatic activity by the drug
[9]
Sulfadoxine‑pyrimethamine 1967 1967 Pfdhps‑Pfdhfr
Mefloquine 1977 1982 Pfmdr1/other Reduction of parasite susceptibility to mefloquine by 
amplification of Pfmdr1 copy number
[93]
Atovaquone 1996 1996 Pfcytb Modification of the drug target by disruption of 
Cytochrome bc1 complex
[8]
Artemisinins 1980s 2006 Pfk13 Quiescence [31, 33]
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characterized by a slow parasite clearance time (72–84 h 
in Pailin and 48–54  h in Wang Pha) and higher failure 
rates (recrudescence) after artesunate monotherapy (in 
Pailin 30 % of patients showed recrudescence compared 
to 10 % in Wang Pha). These altered clinical characteris-
tics were not associated with reduced in  vitro suscepti-
bility, contrasting with observations by Noedl et al. [15]. 
Resistance to artesunate monotherapy first reported in 
western Cambodia and along the Thailand-Myanmar 
border, resulted in lengthening of the parasite clearance 
half-lives from 2.6 h in 2001 to 3.7 h in 2010 [16]. Arte-
misinin resistance is now also established in Myanmar, 
Vietnam, Lao PDR, and China [3].
In order to avoid the spread of P. falciparum resist-
ance, monotherapy with artemisinin or its derivatives 
should be banned [17]. ACT has been recommended 
by the WHO as first-line treatment for uncomplicated 
malaria since 2001 and is nowadays widely used (Addi-
tional file 1). However, in December 2014 eight countries, 
mainly in Africa (Angola, Cabo Verde, Colombia, Equa-
torial Guinea, Gambia, Sao Tome and Principe, Somalia, 
Swaziland) still allowed artemisinin-based monotherapy 
[18].
Treatment failures with ACT have only been observed 
in Asia where, in addition to artemisinin resistance, 
parasites were also resistant to companion drug, e.g. 
mefloquine along the Thai-Myanmar border [19] or pipe-
raquine in Cambodia [20–22]. In such cases, the ACT 
used is replaced by another one and the therapeutic effi-
cacy of the replacement ACT must be monitored every 
2  years as recommended by the WHO [2] for timely 
adaptation of the treatment policy. The threshold of 10 % 
cases with detectable parasites on day 3 after ACT treat-
ment used by the WHO to define areas of artemisinin 
resistance [2] was established in Asia, a region of low/
moderate transmission. In Africa, where transmission is 
usually much higher, artemisinin resistance has not yet 
been reported. However, a recent study suggested that a 
threshold of 5 % cases on day 3 parasite positivity is more 
suited to artemisinin resistance monitoring in Africa due 
to higher levels of acquired immunity against Plasmo-
dium in African populations contributing to faster para-
site clearance [23].
Phenotypic and genotypic basis of artemisinin resistance
It is striking to note that from chloroquine resistance 
in 1957 to artemisinin resistance in 2006 [13], all anti-
malarial drug resistance plaguing Asia was first reported 
at the Thai-Cambodian border and more especially in 
Pailin Province. Poor access to medicines, generating traf-
fic of counterfeit drugs, with sub-clinical quantities, use 
of monotherapy, combined with an intense and exten-
sive migrant labour system, are potential contributors 
[24–26]. No correlation was found between an increased 
mutation rate of the parasite genome and drug resistance 
in these regions, invalidating the hypothesis of the exist-
ence of a ‘hypermutator’ parasite [27]. Resistance in this 
region has a typical multi-resistance profile, with resist-
ance mutations in Pfcrt, Pfdhps, Pfdhfr, Pfmdr1 fixed in 
the parasite populations [28, 29].
Resistance to artemisinins was selected from such 
multi-resistant parasites circulating in western Cam-
bodian provinces and was shown to be an inheritable 
genetic trait of the parasites [16, 30]. The mechanism 
driving artemisinin resistance was discovered using an 
experimental model, the F32-ART line -a highly arte-
misinin-resistant line- established in  vitro after 5  years 
of exposure to escalating concentrations of artemisinin 
[31]. Artemisinin resistance of F32-ART is mediated 
by a resistance mechanism quite distinct from those 
previously described [15, 31–33] (Table  1), since these 
parasites score susceptible using the standard in  vitro 
susceptibility assays [31, 33–35]. Plasmodium resistance 
to artemisinins is due to the enhanced number of young 
ring forms to enter into a quiescence state upon expo-
sure to artemisinins, and quickly resume growth once 
the artemisinins are removed. This capacity is conferred 
by mutations of a gene called Pfk13 [15, 31, 33]. This 
gene is now currently monitored to follow artemisinin 
resistance spread according to WHO recommendations 
[2, 18, 36].
Plasmodium falciparum resistance to artemisinin is 
quiescence-based
The first hypothesis of artemisinin resistance based on 
a partial cytostatic effect of the drug was evoked thanks 
to a mathematical model in 2000 [37]. The classical defi-
nition of quiescence is ‘a reversible absence of prolifera-
tion’, i.e., a non-dividing cell which eventually restarts its 
cell cycle when conditions become appropriate. Various 
quiescent states may depend on the cell history; alter-
natively, quiescence can be the convergence of an adap-
tive process to cope with an adverse environment and an 
active preparation to efficiently resume proliferation [38]. 
The development cycle of P. falciparum presents normal 
arrest at the sporozoite stage in the mosquito salivary 
glands or at the gametocyte stage in red blood cells. In 
vitro, P. falciparum cell cycle progression can be strongly 
delayed at the trophozoite stage in response to isoleucine 
starvation [39]. A fraction of P. vivax and Plasmodium 
ovale sporozoites is able to stop its cell cycle during the 
hepatic phase to enter into a particular state, named hyp-
nozoites, another form of dormant or quiescent parasites, 
and responsible for relapses, all under an epigenetic con-
trol of gene expression by histone modification enzymes 
[40].
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Quiescence and artemisinin‑resistant parasite stages
Data obtained with the highly artemisinin-resistant 
F32-ART line and P. falciparum isolates showed that 
artemisinin pressure induces developmental arrest of a 
sub-population of very young (0–3 h) ring stages which 
enter a quiescent state, while killing all other stages [31, 
41]. Quiescence has also been correlated with K13-medi-
ated artemisinin resistance in field isolates [33].
Quiescent parasites are difficult to identify under the 
microscope but staining mitochondrial activity with fluo-
rescent dyes, unambiguously labels live quiescent cells in 
artemisinin-treated cultures [31, 42, 43]. Cell cycle arrest 
leads to overestimations of the parasite clearance time 
in patients [44], and a defect of H3-hypoxanthine incor-
poration in standard chemosensitivity assay leads to an 
overestimation of the effectiveness (IC50) of anti-malarials 
[31, 42]. As a result, classical susceptibility assays based 
on parasite proliferation are not suitable to differentiate 
parasites that are artemisinin-resistant from those that are 
artemisinin-sensitive. Recrudescence assays and ring stage 
survival assay (RSA0–3h) using highly synchronized P. fal-
ciparum parasites in culture, based on a 6-h dihydroarte-
misinin exposure in vitro, followed by culture in drug-free 
conditions until microscopic read-out at 72 h, are able to 
detect and quantify artemisinin resistance [31, 35, 41]. 
Quiescence takes place at a moment of the parasite cycle 
(young ring stage) where artemisinin is less efficient [43]. 
Indeed, artemisinin toxicity is potentiated by products 
of haemoglobin digestion inside the food vacuole, which 
begins in the mid-ring stage. Haemoglobin degradation 
products, such as haem and ferrous iron, react with arte-
misinin to cause oxidative stress and irreversible dam-
ages [45]. The low levels of haemoglobin endocytosis and 
therefore its absence or low digestion level in very young 
rings, could explain their reduced sensitivity. At this stage, 
which is approximately 14 h longer in resistant parasites 
than in wild-type parasites [46], a lower (moderate) oxida-
tive stress is likely more manageable by the parasite, and 
particularly so by PfK13 mutants, while at the tropho-
zoite stage, artemisinin-dependent damage exceeds the 
parasite’s response abilities [43]. The ring stage arrested 
development allows parasites to survive during the rela-
tively short period of elevated artemisinin concentration 
(the elimination half-life in humans varies from one to 
11 h depending on the derivative) [31, 41, 47]. Why only a 
small sub-set population (<1 %) of resistant parasites [42] 
is able to enter a quiescence stage despite their common 
genetic pattern remains to be elucidated.
Response of non‑mutated PfK13 parasites to artemisinin 
exposure
It appears that all parasite lines are able to enter quies-
cence or dormancy-mediated processes [48]. In vitro, 
this is monitored by the capacity to proliferate after drug 
removal, i.e., to recrudesce. Artemisinin-resistance is 
characterized by a short time to recrudescence as dem-
onstrated with the F32-ART (artemisinin-resistant) and 
F32-TEM (sensitive) sibling laboratory lines. After expo-
sure to up to 18  µM of artemisinin, F32-TEM was able 
to resume growth and reach 5 % of parasitaemia 17 days 
after artemisinin removal compared to 10 days for F32-
ART [31]. Other studies reported that several arte-
misinin-sensitive P. falciparum strains restarted their cell 
cycle from 4 to 25 days after the drug removal [48, 49]. 
Thus, some wild-type parasites are able to survive arte-
misinin exposure but artemisinin-resistant strains restart 
faster with more quiescent parasites and/or quicker 
awakening [31, 35].
Involvement of the Pfk13 locus in Plasmodium falciparum 
resistance to artemisinins
Pfk13 polymorphism
Whole genome-sequencing of F32-ART and its sibling-
sensitive line F32-TEM as well as of artemisinin-resistant 
P. falciparum isolates from Cambodia, allowed arte-
misinin resistance to be associated with mutations of 
the K13 protein (accession number PF3D7_1343700), 
belonging to the kelch super-family of proteins. All muta-
tions found in the Pfk13 gene and correlated with arte-
misinin resistance are non-synonymous, and are present 
after position 440 in the propeller domain (K13-propel-
ler) [33, 36, 50]. Just one of these mutations is sufficient 
to confer artemisinin-resistance [50]. There is a strong 
genetic correlation in Asia between K13-propeller muta-
tion and a slow parasite clearance time (half-life longer 
than 5 h) [3, 28, 33, 36, 51–53]. In Myanmar, among the 
K13 mutations observed, C580Y and M476I (the muta-
tion acquired by F32-ART parasites) were associated with 
delayed clearance-time [54]. In Southern China, at the 
Myanmar border, the single F446I mutation predomi-
nates and is associated with delayed clearance [52]. The 
current picture is that artemisinin-resistant parasites cir-
culating in different geographic areas of Southeast Asia 
stem from several independent emergences of unique 
mutations in the K13-propeller domain [28, 36, 53] where 
the parasite genetic background could play a role in the 
propensity of K13 mutants to emerge. Three prevalent 
K13-propeller mutations -C580Y, R539T and Y493H- 
were shown to correlate strongly with increased parasite 
clearance in vivo and with increased survival rates in the 
in  vitro RSA0–3h [33, 55, 56]. Gene editing showed that 
introduction of the wild-type allele into resistant parasites 
procured a sensitive, very low RSA0–3h survival rate (0.3–
0.7 %) whereas the parent isolates harbouring a K13 muta-
tion (R539T, I543T or C580Y) displayed 40–49 % RSA0–3h 
survival. Conversely C580Y introduced into wild-type 
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artemisinin-sensitive Cambodian clinical isolates and ref-
erence lines conferred varying degrees of in  vitro resist-
ance, suggesting additional contribution from the genetic 
background [50]. Importantly, Asian K13 mutations are 
generally not found in Africa where numerous additional 
but rare Pfk13 alleles were identified [36, 57–59]. An 
exception is the SNP A578S, observed in many African 
countries [58–60] as well as Bangladesh [51] and Thailand 
[36], however this mutation is not associated with arte-
misinin resistance [36].
Apart from one study in a limited number of African 
children with severe malaria [61], none of the K13 muta-
tions has been associated with clinical artemisinin resist-
ance for the time being, despite evidence that introducing 
the C580Y mutation generates artemisinin resistance 
in  vitro in the NF54 parasite strain considered to be of 
African origin [62]. Genetic determinants of artemisinin 
resistance have been reviewed recently by Fairhurst [63]. 
A search of mutations in the k13 P. vivax orthologue 
showed reduced polymorphism compared to Pfk13 and 
the V552I mutation identified cannot be currently associ-
ated with any P. vivax drug resistance [64].
PfK13 activity
The exact function of PfK13 in Plasmodium is not known 
yet, but analogies are possible with the human Keap1 
protein function, in particular, in the cell response to oxi-
dative stress (Fig. 1). PfK13 and Keap1 share homologies 
in the C-terminal BTB/POZ and the 6-kelch propeller 
domains [33, 65]. The presence of a BTB/POZ domain 
suggests that PfK13 could dimerize like Keap1. Forma-
tion of a dimer has been experimentally confirmed in 
the recently solved crystal structure of the PfK13 BTB/
POZ propeller domain [66]. Based on Keap1 function, a 
hypothetical model could be that in steady state condi-
tions, the wild-type K13-propeller domain binds to uTF 
(a putative, unidentified transcription factor functionally 
equivalent to human Nrf2) allowing its ubiquitination 
and proteosomal degradation. This ubiquitination could 
be mediated by one of the Plasmodium ubiquitin ligases 
but this has not yet been investigated. Importantly, the 
putative uTF transcription factor remains to be identi-
fied in the Plasmodium genome [67]. Recently, P. falcipa-
rum phosphatidylinositol 3 kinase (PfPI3K) was shown to 
undergo a PfK13-dependent ubiquitinylation. It could be 
immuno-precipitated in a complex with PfK13 [68] and 
has been included as a complex with PfK13 illustrated in 
Fig. 1, but direct binding of PfPI3K to PfK13 remains to 
be demonstrated [68].
Biochemical consequences of a mutant K13 propeller
Based on Keap1 involvement in human lung cancer 
[69] and hypertension [70], it is possible to predict that 
K13-propeller mutations altering the propeller structure 
impair its biological function and interaction with part-
ner proteins [33]. In particular, K13-propeller mutations 
would prevent fixation of uTF to the propeller domain, 
and as a consequence reduce the ubiquitinylation-
dependent turnover, promoting translocation of uTF to 
the nucleus (Fig. 2).
In C580Y mutant parasites, PfPI3K was no longer ubiq-
uitinylated, resulting in 1.5–twofold increased basal PI3P 
levels. This may reflect disrupted interactions between 
PfPI3K and PfK13 or disrupted interactions within the 
PfK13 associated protein complex (Fig.  2). Elevated 
basal phosphatidylinositol 3 phosphate (PI3P) levels 
appear central to artemisinin resistance, as K13 wild-type 
parasites became resistant upon elevation of PI3P lev-
els induced by transgenic expression of human VPS34. 
Similarly transgenic elevation of PfAKT (also known as 
protein kinase B) in a wild-type parasite confers in vitro 
artemisinin resistance in connection with increased lev-
els of PI3P by a feedback mechanism supposed [68]. As 
PfPI3K enzymatic activity is inhibited by artemisinins, 
the levels of PI3P likely drop rapidly upon exposure to 
artemisinins in sensitive parasites, whereas the PI3P level 
is already elevated in resistant parasites [68]. Additional 
downstream effectors likely come into play to orchestrate 
the quiescence response to artemisinin and withstand its 
toxicity.
PfK13 polymorphisms are also associated with modi-
fications of endoplasmic reticulum homeostasis (Fig. 2). 
Indeed, transcriptome analysis of P. falciparum isolates 
revealed that artemisinin resistance is associated with 
increased expression of a network of molecular chaper-
ones and major protein complexes belonging to the UPR 
pathway. In particular, immunoglobulin-binding pro-
tein (BiP) and cyclophilin B (CYPB), belonging to the 
Plasmodium reactive oxidative stress complex involved 
in protein folding and repair in the endoplasmic reticu-
lum, are upregulated. Along the same line, the endoplas-
mic reticulum-resident calcium-binding protein (ERC) 
involved in endoplasmic reticulum Ca2+ homeostasis is 
also overexpressed [71, 72]. This upregulation of UPR in 
PfK13 mutants likely endows the parasite with increased 
ability to repair or degrade proteins damaged by alkyla-
tion and oxidation generated by artemisinin [73]. Based 
on homology with the human BiP-PERK-eIF2α pathway 
involved in the cell cycle arrest under stress conditions 
(Fig.  3) [74, 75], BiP bound to misfolded/altered pro-
teins could dissociate from the PERK homologue, PfPK4, 
leading to its activation, and phosphorylation of eIF2α, 
which could trigger parasite cell cycle arrest via cyclin-
dependent kinases, inhibition of protein synthesis, and 
the translocation of an unidentified transcription factor 
uTF into the nucleus. In mammalian cells, the PI3K/AKT 
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pathway participates in UPR regulation and the activated 
AKT protein (also known as protein kinase B) seems to 
be required for Protein kinase RNA-like endoplasmic 
reticulum kinase (PERK)-mediated eIF2α phosphoryla-
tion [76]. This is reminiscent of the Plasmodium cell cycle 
slow down and activation of eIF2α kinases (PfeIK1 and 
PfeIK2) induced by amino acid starvation and observed 
in sporozoite latency inside mosquito salivary glands [39, 
77]. Translocation of uTF could, in addition, be favoured 
by its phosphorylation by PfPK4 and also, like in humans, 
Fig. 1 The Keap1 complex in human cells and a hypothetical PfK13 complex
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by PfPI3K, and could activate the expression of Plasmo-
dium UPR and cytoprotective genes (Fig. 2).
This model does not exclude the existence of more 
than one uTF. Moreover, the PfPK4/PfPI3K downstream 
regulation cascades remain to be elucidated and experi-
mentally demonstrated (Fig.  2). The involvement of 
the PfAKT pathway in artemisinin resistance, like PI3P 
involvement, still remains to be detailed. Moreover, the 
exact kinetics of events once the parasites are exposed to 
artemisinin oxidative and alkylating damage needs to be 
clarified, in particular as PI3K is inhibited by artemisinins 
[68] and should no longer contribute to refuelling PI3P 
levels.
Artemisinin resistance possibly includes a combination 
of the increased degradation of misfolded proteins/repair 
of damaged proteins especially those involved in the 
cell cycle progression and the ‘PfPK4/PfPI3K’ mediated 
response to the artemisinins’ oxidative stress. This cellu-
lar response of K13 mutant parasites to artemisinin stress 
could lead to a sub-set of ring stage parasites to enter 
into a quiescence state (Fig. 2). Why only a sub-set and 
a variable fraction of ring stages is involved needs to be 
understood. It may reflect a finely tuned balance between 
different cellular effectors that is unequally distributed 
between individual infected cells.
Artemisinin-induced quiescence and Plasmodium 
metabolism
Dihydroartemisinin (DHA)-induced quiescence in non-
mutated PfK13 parasites is associated with suspended 
RNA, DNA and protein synthesis [49]. Folate metabo-
lism, isoprenoid metabolism, lactate dehydrogenase 
activity and glycolysis, the main metabolic pathway 
producing adenosine triphosphate (ATP) and phospho-
enolpyruvate (PEP) in Plasmodium, are severely down-
regulated [49]. But, even though the metabolism of 
quiescent parasites is largely down-phased, some path-
ways remain active and require another source of ATP 
and PEP, depending on pyruvate production by the api-
coplast and on mitochondrial activity (Fig.  4) [49, 78]. 
In DHA-induced quiescent rings, among the genes 
that remain actively transcribed, are genes coding for 
enzymes of the pyruvate metabolism (pyruvate kinase 2, 
pyruvate dehydrogenase E1 beta subunit), the fatty acid 
metabolism by FASII -fatty acid synthesis type II- path-
way (biotin acetyl-CoA carboxylase, enoyl-acyl carrier 
Fig. 2 Mechanism proposed for PfK13‑mediated resistance to artemisinins in K13 mutated Plasmodium falciparum at young ring stage. K13‑pro‑
peller mutation prevents the fixation of uTF and PI3K to the Kelch domain and their ubiquitination, leading to enhanced concentration of PI3P. The 
artemisinin‑induced oxidative stress is responsible for the accumulation of misfolded proteins in the ER endoplasmic reticulum. Misfolded proteins 
bind to BiP, the complex BiP‑PfPK4 is dissociated and PfPK4 phosphorylates uTF and elF2α. elF2α phosphorylation should allow the translocation of 
uTF in the nucleus to regulate UPR targets and cytoprotective gene expression and also inhibit protein synthesis [75]. BiP immunoglobulin‑binding 
protein, BTB broad‑complex, tramtrack and Bric a Brac, CYPB cyclophilin B, eIF2α eukaryotic translation initiation factor 2α, ERC endoplasmic reticu‑
lum resident calcium binding protein, PfPK4 P. falciparum protein kinase 4, PI3K phosphatidylinositol 3 kinase, PI3P phosphatidylinositol 3 phosphate, 
uTF unidentified transcription factor(s)
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reductase/FabI) and for the lipoic acid metabolism (lipoic 
acid synthase) [49]. The mitochondrial tricarboxylic acid 
cycle is down-regulated but remains active and genes 
encoding the proteins of the electron transport chain 
also remain transcribed at a normal level (cytochrome c 
subunit II, NADH-ubiquinone oxidoreductase II, flavo-
protein sub-unit of succinate dehydrogenase and ubiqui-
nol cytochrome c reductase iron sulfur sub-unit) [49]. 
This was confirmed by rhodamine staining of parasite 
after DHA treatment: only rhodamine-positive parasites 
resumed growth [42]. In stress conditions, depletion of 
host-derived fatty acids induces an upregulation of the 
Plasmodium FASII pathway [79]. PI3P is present in the 
apicoplast membrane and can play a role in exchanges of 
protein and likely lipids [80–82] with the adjacent mito-
chondrion. The elevated production of PI3P in resistant 
parasites [68] could play a role in the maintenance of this 
minimal energetic metabolism based on mitochondrial 
and apicoplast activity and also found in quiescent resist-
ant parasites [49]. Indeed these parasites cannot survive 
and resume growth in the presence of atovaquone, an 
inhibitor of the mitochondrial activity, and the use of 
haloxyfob, an acetyl-CoA carboxylase inhibitor, as well 
as triclosan, an inhibitor of FabI delays the recovery of 
DHA-induced quiescent parasites [35, 42, 49, 83, 84], 
demonstrating that this minimum active metabolism 
during the induced quiescence state by artemisinins is 
essential for the survival and the recovery of the parasites 
from dormancy.
Thus, the quiescent state induced at the young ring 
stage by artemisinin in sensitive and resistant parasites 
likely seems to involve the same cellular mechanisms, but 
the PfK13 mutation shifts the intra-population distribu-
tion so as to allow more parasites to become quiescent 
in the case of resistant parasites, and to quickly resume 
growth after the drug removal in vitro or drug elimina-
tion in patients.
Conclusions
It is increasingly clear that the P. falciparum resistance 
to artemisinin and its derivatives is not due to efflux 
modulation or target modifications as described for 
other anti-malarials, but is based on increased capacity 
of PfK13-mutant parasites to manage oxidative damage 
thanks to greater UPR mobilization. The over-expres-
sion of UPR target genes should impact three key points: 
(an) unidentified transcription factor(s) (uTF) regulat-
ing transcription of UPR/oxidative response genes, the 
PI3  K/PI3P/AKT pathway activity and the PfPK4/eIF2α 
cascade. This would allow parasite entrance into a qui-
escence state with minimal energy metabolism provided 
by the apicoplast and the mitochondrion, maintained by 
alternative tricarboxylic acid cycle and FASII metabolism, 
until drug removal/excretion when parasites can resume 
growth. Recently, the artemisinin-resistant F32-ART line, 
selected by long-term drug pressure with solely arte-
misinin, was shown to display an extended age range of 
stages surviving artemisinin treatment extending to older 
ring stages (13–16 h) and even trophozoite stages. These 
parasites were also able to survive lethal doses of diverse 
classes of anti-malarial drugs, including molecules used 
as partners in currently recommended ACT, in the 
Fig. 3 Bip‑PERK‑eIF2α pathway
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absence of the ‘classical’ mutations of the target genes for 
these drugs. Thus, long-term in  vitro artemisinin expo-
sure selects a novel multidrug tolerant phenotype, which 
could represent a major threat to anti-malarial drug pol-
icy in the field [35]. This threat is exacerbated by the fact 
that artemisinin-resistant parasites seem able to infect 
and be transmitted by a large panel of Anopheles species, 
including the major African species Anopheles gambiae 
[85]. This is yet a another reason to urgently clarify the 
cellular network of ART resistance in order to identify 
new therapeutic modalities (to protect the molecules 
currently used), and/or novel drug development, in order 
to avoid entrance into a quiescent state, target quiescent 
parasites and promote restart of the cell cycle, rescuing 
drug susceptibility of parasites.
Authors’ contributions
JMA and FBV designed the review; all authors contributed to acquisition, 
analysis and interpretation of data. LP, APR, OMP, JMA, and FBV have been 
Additional file
Additional file 1. ACT recommended by WHO and the newly approved 
combination DHA‑piperaquine.
Fig. 4 Synthetic model of Plasmodium quiescence metabolism. Quiescent P. falciparum parasites demonstrated an arrested glycolysis pathway 
leading to suspended production of ATP and phosphoenolpyruvate. Basal metabolism is maintained in quiescent parasites due to FASII metabolism 
in the apicoplast coupled with ATP production in the mitochondrion. Haloxifob, triclosan and atovaquone can disrupt these biochemical pathways 
[49, 95]. Green protein/enzyme with maintained expression in quiescent rings [49]. ACC acetyl‑CoA carboxylase, ACO aconitase, BCKDH branched‑
chain keto acid dehydratase, coxii cytochrome c sub‑unit II, CS citrate synthase, FabI enoyl‑ACP reductase, FabZ β‑hydroxyacyl‑ACP dehydratase, 
FabG β‑ketoacyl‑ACP reductase, FabB/F β‑ketoacyl‑ACP synthase I/II, FabH β‑ketoacyl‑ACP synthase III, FabD malonyl‑CoA:ACP transacylase, FASII 
fatty acid synthesis type II, FH fumarate hydratase, IDH isocitrate dehydrogenase, KDH α‑ketoglutarate dehydrogenase, LDH lactate dehydrogenase, 
LipA lipoic acid synthase, LipB octanoyl‑ACP protein transferase, MQO malate quinone oxidoreductase, ndh2 NADH‑ubiquinone oxidoreductase II, 
PEP phosphoenolpyruvate, PEPCase PEP carboxylase, PEPCK PEP carboxykinase, PDH pyruvate dehydrogenase, PYK pyruvate kinase, SCS succinyl‑CoA 
synthase, SDH succinate dehydrogenase, sdha flavoprotein subunit of succinate dehydrogenase, TCA Tri carboxylic acid, uqcr iron sulfur sub‑unit of 
ubiquinol Cytochrome c reductase [49, 83, 95]
Page 10 of 12Paloque et al. Malar J  (2016) 15:149 
involved in drafting and revising the manuscript critically. All authors read and 
approved the final manuscript.
Authors’ information
OM‑P and FB‑V are co‑inventors on the pending patents #US61/904651 and 
US62/062439, filed by Institut Pasteur. These patents cover the use of K13 
mutations as a molecular marker of P. falciparum ART resistance.
Author details
1 CNRS, LCC (Laboratoire de Chimie de Coordination) UPR8241, 205 route de 
Narbonne, BP 44099, 31077 Toulouse Cedex 4, France. 2 Université de Tou‑
louse, UPS, INPT, 31077 Toulouse Cedex 4, France. 3 Present Address: Depart‑
ment of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah 
Mada, Yogyakarta, Indonesia. 4 Unité d’Immunologie Moléculaire des Parasites, 
Institut Pasteur, 75015 Paris, France. 
Acknowledgements
This study was supported in part by the French Agence Nationale de la 
Recherche (Grant ANR‑13‑BSV3‑0018‑01) and by the French Government pro‑
gramme Investissement d’Avenir, Laboratoire d’Excellence “Integrative Biology 
of Emerging Infectious Diseases” (Grant ANR‑10‑LABX‑62‑IBEID).
Competing interests
The authors declare that they have no competing interests.
Received: 19 December 2015   Accepted: 1 March 2016
References
 1. Nobel price. http://www.nobelprize.org/nobel_prizes/medicine/laure‑
ates/2015/. 2015.
 2. WHO. Status report on artemisinin and ACT resistance. Geneva: World 
Health Organization; 2015.
 3. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. 
Spread of artemisinin resistance in Plasmodium falciparum malaria. N 
Engl J Med. 2014;371:411–23.
 4. Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. Plasmo-
dium falciparum dihydroartemisinin‑piperaquine failures in Cambodia 
are associated with mutant K13 parasites presenting high survival rates 
in novel piperaquine in vitro assays: retrospective and prospective 
investigations. BMC Med. 2015;13:305.
 5. Lubell Y, Dondorp A, Guerin PJ, Drake T, Meek S, Ashley E, et al. Arte‑
misinin resistance–modelling the potential human and economic 
costs. Malar J. 2014;13:452.
 6. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial 
actions of quinoline drugs. Life Sci. 2004;74:1957–72.
 7. Robert A, Benoit‑Vical F, Claparols C, Meunier B. The antimalarial drug 
artemisinin alkylates heme in infected mice. Proc Natl Acad Sci USA. 
2005;102:13676–80.
 8. Kessl JJ, Meshnick SR, Trumpower BL. Modeling the molecular basis 
of atovaquone resistance in parasites and pathogenic fungi. Trends 
Parasitol. 2007;23:494–501.
 9. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to 
antifolates. Pharmacol Rev. 2005;57:117–45.
 10. Bruce‑Chwatt L. Chemotherapy of malaria. Geneva: World Health 
Organization; 1986. p. 245.
 11. Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ. The diminishing 
returns of atovaquone‑proguanil for elimination of Plasmodium falcipa-
rum malaria: modelling mass drug administration and treatment. Malar 
J. 2014;13:380.
 12. Durand R, Prendki V, Cailhol J, Hubert V, Ralaimazava P, Massias L, et al. 
Plasmodium falciparum malaria and atovaquone‑proguanil treatment 
failure. Emerg Infect Dis. 2008;14:320–2.
 13. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence 
of artemisinin‑resistant malaria in western Cambodia. N Engl J Med. 
2008;359:2619–20.
 14. Noedl H, Socheat D, Satimai W. Artemisinin‑resistant malaria in Asia. N 
Engl J Med. 2009;361:540–1.
 15. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte‑
misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 
2009;361:455–67.
 16. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. 
Emergence of artemisinin‑resistant malaria on the western border of 
Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
 17. WHO. Guidelines for the treatment of malaria. Geneva: World Health 
Organization; 2010.
 18. WHO. World malaria report 2014. Geneva: World Health Organization; 
2014.
 19. Na‑Bangchang K, Muhamad P, Ruaengweerayut R, Chaijaroenkul W, 
Karbwang J. Identification of resistance of Plasmodium falciparum to 
artesunate‑mefloquine combination in an area along the Thai‑Myan‑
mar border: integration of clinico‑parasitological response, systemic 
drug exposure, and in vitro parasite sensitivity. Malar J. 2013;12:263.
 20. Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin‑piperaquine 
failure in Cambodia. N Engl J Med. 2014;371:484–5.
 21. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. 
Evidence of Plasmodium falciparum malaria multidrug resistance to 
artemisinin and piperaquine in Western Cambodia: dihydroartemisinin‑
Piperaquine open‑label multicenter clinical assessment. Antimicrob 
Agents Chemother. 2015;59:4719–26.
 22. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, 
et al. Dihydroartemisinin‑piperaquine failure associated with a triple 
mutant including kelch13 C580Y in Cambodia: an observational cohort 
study. Lancet Infect Dis. 2015;15:683–91.
 23. WWARN. Clinical determinants of early parasitological response to 
ACTs in African patients with uncomplicated falciparum malaria: a 
literature review and meta‑analysis of individual patient data. BMC Med. 
2015;13:212.
 24. Packard RM. The origins of antimalarial‑drug resistance. N Engl J Med. 
2014;371:397–9.
 25. Smith Gueye C, Newby G, Hwang J, Phillips AA, Whittaker M, MacArthur 
JR, et al. The challenge of artemisinin resistance can only be met by 
eliminating Plasmodium falciparum malaria across the Greater Mekong 
subregion. Malar J. 2014;13:286.
 26. Samarasekera U. Countries race to contain resistance to key antima‑
larial. Lancet. 2009;374:277–80.
 27. Brown TS, Jacob CG, Silva JC, Takala‑Harrison S, Djimde A, Dondorp 
AM, et al. Plasmodium falciparum field isolates from areas of repeated 
emergence of drug resistant malaria show no evidence of hypermuta‑
tor phenotype. Infect Genet Evol. 2015;30:318–22.
 28. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro‑Garcia J, Amara‑
tunga C, et al. Genetic architecture of artemisinin‑resistant Plasmodium 
falciparum. Nat Genet. 2015;47:226–34.
 29. Khim N, Bouchier C, Ekala MT, Incardona S, Lim P, Legrand E, et al. Coun‑
trywide survey shows very high prevalence of Plasmodium falciparum 
multilocus resistance genotypes in Cambodia. Antimicrob Agents 
Chemother. 2005;49:3147–52.
 30. Anderson TJ, Nair S, Nkhoma S, Williams JT, Imwong M, Yi P, et al. 
High heritability of malaria parasite clearance rate indicates a genetic 
basis for artemisinin resistance in western Cambodia. J Infect Dis. 
2010;201:1326–30.
 31. Witkowski B, Lelievre J, Barragan MJ, Laurent V, Su XZ, Berry A, et al. 
Increased tolerance to artemisinin in Plasmodium falciparum is medi‑
ated by a quiescence mechanism. Antimicrob Agents Chemother. 
2010;54:1872–7.
 32. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, 
et al. Exploring the contribution of candidate genes to Artemisinin 
resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 
2010;54:2886–92.
 33. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, 
et al. A molecular marker of artemisinin‑resistant Plasmodium falcipa-
rum malaria. Nature. 2014;505:50–5.
 34. Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P, 
Kyle DE. Open randomized trial of oral artemether alone and a sequen‑
tial combination with mefloquine for acute uncomplicated falciparum 
malaria. Am J Trop Med Hyg. 1997;56:613–7.
 35. Ménard S, Ben Haddou T, Ramadani AP, Ariey F, Iriart X, Beghain J, 
et al. Induction of multidrug tolerance in Plasmodium falciparum by 
extended artemisinin pressure. Emerg Infect Dis. 2015;21:1733–41.
Page 11 of 12Paloque et al. Malar J  (2016) 15:149 
 36. Ménard D, Khim N, Beghain J, Adegnika A, Alam M, Amodu O et al. A 
worldwide map of Plasmodium falciparum artemisinin resistance. N 
Engl J Med. 2016. (in press).
 37. Hoshen MB, Na‑Bangchang K, Stein WD, Ginsburg H. Mathematical 
modelling of the chemotherapy of Plasmodium falciparum malaria 
with artesunate: postulation of ‘dormancy’, a partial cytostatic effect 
of the drug, and its implication for treatment regimens. Parasitology. 
2000;121:237–46.
 38. Daignan‑Fornier B, Sagot I. Proliferation/quiescence: the controversial 
“aller‑retour”. Cell Div. 2011;6:10.
 39. Babbitt SE, Altenhofen L, Cobbold SA, Istvan ES, Fennell C, Doerig 
C, et al. Plasmodium falciparum responds to amino acid starva‑
tion by entering into a hibernatory state. Proc Natl Acad Sci USA. 
2012;109:E3278–87.
 40. Dembele L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CH, 
et al. Persistence and activation of malaria hypnozoites in long‑term 
primary hepatocyte cultures. Nat Med. 2014;20:307–12.
 41. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced 
artemisinin susceptibility of Plasmodium falciparum ring stages in 
western Cambodia. Antimicrob Agents Chemother. 2013;57:914–23.
 42. Peatey CL, Chavchich M, Chen N, Gresty KJ, Gray KA, Gatton ML, et al. 
Mitochondrial membrane potential in a small subset of Artemisinin‑
induced dormant Plasmodium falciparum parasites in vitro. J Infect Dis. 
2015;212:426–34.
 43. Klonis N, Crespo‑Ortiz MP, Bottova I, Abu‑Bakar N, Kenny S, Rosenthal 
PJ, et al. Artemisinin activity against Plasmodium falciparum 
requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA. 
2011;108:11405–10.
 44. Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, et al. Tar‑
geting the cell stress response of Plasmodium falciparum to overcome 
artemisinin resistance. PLoS Biol. 2015;13:e1002132.
 45. Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, et al. Haem‑activated 
promiscuous targeting of artemisinin in Plasmodium falciparum. Nat 
Commun. 2015;6:10111.
 46. Hott A, Casandra D, Sparks KN, Morton LC, Castanares GG, Rutter A, et al. 
Artemisinin‑resistant Plasmodium falciparum parasites exhibit altered 
patterns of development in infected erythrocytes. Antimicrob Agents 
Chemother. 2015;59:3156–67.
 47. Saralamba S, Pan‑Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh 
N, et al. Intrahost modeling of artemisinin resistance in Plasmodium 
falciparum. Proc Natl Acad Sci USA. 2011;108:397–402.
 48. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. Artemisinin‑
induced dormancy in Plasmodium falciparum: duration, recovery rates, 
and implications in treatment failure. J Infect Dis. 2010;202:1362–8.
 49. Chen N, LaCrue AN, Teuscher F, Waters NC, Gatton ML, Kyle DE, et al. 
Fatty acid synthesis and pyruvate metabolism pathways remain active 
in dihydroartemisinin‑induced dormant ring stages of Plasmodium 
falciparum. Antimicrob Agents Chemother. 2014;58:4773–81.
 50. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani 
AP, et al. Drug resistance. K13‑propeller mutations confer arte‑
misinin resistance in Plasmodium falciparum clinical isolates. Science. 
2015;347:428–31.
 51. Mohon AN, Alam MS, Bayih AG, Folefoc A, Shahinas D, Haque R, et al. 
Mutations in Plasmodium falciparum K13 propeller gene from Bangla‑
desh (2009‑2013). Malar J. 2014;13:431.
 52. Huang F, Takala‑Harrison S, Jacob CG, Liu H, Sun X, Yang H, et al. A single 
mutation in K13 predominates in Southern China and is associated 
with delayed clearance of Plasmodium falciparum following artemisinin 
treatment. J Infect Dis. 2015;212:1629–35.
 53. Takala‑Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp 
AM, et al. Independent emergence of artemisinin resistance muta‑
tions among Plasmodium falciparum in Southeast Asia. J Infect Dis. 
2015;211:670–9.
 54. Nyunt MH, Hlaing T, Oo HW, Tin‑Oo LL, Phway HP, Wang B, et al. Molecu‑
lar assessment of artemisinin resistance markers, polymorphisms in 
the k13 propeller, and a multidrug‑resistance gene in the eastern and 
western border areas of Myanmar. Clin Infect Dis. 2015;60:1208–15.
 55. Amaratunga C, Witkowski B, Dek D, Try V, Khim N, Miotto O, et al. 
Plasmodium falciparum founder populations in western Cambodia have 
reduced artemisinin sensitivity in vitro. Antimicrob Agents Chemother. 
2014;58:4935–7.
 56. Amaratunga C, Witkowski B, Khim N, Menard D, Fairhurst RM. 
Artemisinin resistance in Plasmodium falciparum. Lancet Infect Dis. 
2014;14:449–50.
 57. Sibley CH. Understanding artemisinin resistance. Science. 
2015;347:373–4.
 58. Kamau E, Campino S, Amenga‑Etego L, Drury E, Ishengoma D, Johnson 
K, et al. K13‑propeller polymorphisms in Plasmodium falciparum para‑
sites from sub‑Saharan Africa. J Infect Dis. 2015;211:1352–5.
 59. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Green‑
wood BM, et al. Absence of putative artemisinin resistance mutations 
among Plasmodium falciparum in sub‑Saharan Africa: a molecular 
epidemiologic study. J Infect Dis. 2014;211:680–8.
 60. Maiga‑Ascofare O, May J. Is the A578S Single‑Nucleotide Polymorphism 
in K13‑propeller a marker of emerging resistance to artemisinin among 
Plasmodium falciparum in Africa? J Infect Dis. 2016;213:165–6.
 61. Hawkes M, Conroy AL, Opoka RO, Namasopo S, Zhong K, Liles WC, et al. 
Slow clearance of Plasmodium falciparum in severe pediatric Malaria, 
Uganda, 2011–2013. Emerg Infect Dis. 2015;21:1237–9.
 62. Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, 
Lopez‑Rubio JJ. Genome editing in the human malaria parasite 
Plasmodium falciparum using the CRISPR‑Cas9 system. Nat Biotechnol. 
2014;32:819–21.
 63. Fairhurst RM. Understanding artemisinin‑resistant malaria: what a differ‑
ence a year makes. Curr Opin Infect Dis. 2015;28:417–25.
 64. Popovici J, Kao S, Eal L, Bin S, Kim S, Menard D. Reduced polymorphism 
in the Kelch propeller domain in Plasmodium vivax isolates from Cam‑
bodia. Antimicrob Agents Chemother. 2015;59:730–3.
 65. Adams J, Kelso R, Cooley L. The kelch repeat superfamily of proteins: 
propellers of cell function. Trends Cell Biol. 2000;10:17–24.
 66. Protein Data Bank. Crystal structure analysis of Kelch protein from 
Plasmodium falciparum. http://www.rcsb.org/pdb/explore/explore.
do?structureId=4yy8. 2015.
 67. Winzeler EA, Manary MJ. Drug resistance genomics of the antimalarial 
drug artemisinin. Genome Biol. 2014;15:544.
 68. Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, 
et al. A molecular mechanism of artemisinin resistance in Plasmodium 
falciparum malaria. Nature. 2015;520:683–7.
 69. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, 
et al. Structural basis for defects of Keap1 activity provoked by its point 
mutations in lung cancer. Mol Cell. 2006;21:689–700.
 70. Boyden LM, Choi M, Choate KA, Nelson‑Williams CJ, Farhi A, Toka HR, 
et al. Mutations in kelch‑like 3 and cullin 3 cause hypertension and 
electrolyte abnormalities. Nature. 2012;482:98–102.
 71. Morita M, Sanai H, Hiramoto A, Sato A, Hiraoka O, Sakura T, et al. Plas-
modium falciparum endoplasmic reticulum‑resident calcium binding 
protein is a possible target of synthetic antimalarial endoperoxides, 
N‑89 and N‑251. J Proteome Res. 2012;11:5704–11.
 72. Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, et al. Population 
transcriptomics of human malaria parasites reveals the mechanism of 
artemisinin resistance. Science. 2015;347:431–5.
 73. Liu Y, Lok CN, Ko BC, Shum TY, Wong MK, Che CM. Subcellular localiza‑
tion of a fluorescent artemisinin derivative to endoplasmic reticulum. 
Org Lett. 2010;12:1420–3.
 74. Gosline SJ, Nascimento M, McCall LI, Zilberstein D, Thomas DY, Matlash‑
ewski G, et al. Intracellular eukaryotic parasites have a distinct unfolded 
protein response. PLoS One. 2011;6:e19118.
 75. Kansanen E, Jyrkkänen H‑K, Levonen A‑L. Activation of stress signaling 
pathways by electrophilic oxidized and nitrated lipids. Free Radical Bio 
Med. 2012;52:973–82.
 76. Blaustein M, Perez‑Munizaga D, Sanchez MA, Urrutia C, Grande A, Risso 
G, et al. Modulation of the Akt pathway reveals a novel link with PERK/
eIF2alpha, which is relevant during hypoxia. PLoS One. 2013;8:e69668.
 77. Zhang M, Fennell C, Ranford‑Cartwright L, Sakthivel R, Gueirard P, 
Meister S, et al. The Plasmodium eukaryotic initiation factor‑2alpha 
kinase IK2 controls the latency of sporozoites in the mosquito salivary 
glands. J Exp Med. 2010;207:1465–74.
 78. Salcedo‑Sora JE, Caamano‑Gutierrez E, Ward SA, Biagini GA. The prolif‑
erating cell hypothesis: a metabolic framework for Plasmodium growth 
and development. Trends Parasitol. 2014;30:170–5.
 79. Botte CY, Yamaryo‑Botte Y, Rupasinghe TW, Mullin KA, MacRae JI, 
Spurck TP, et al. Atypical lipid composition in the purified relict 
Page 12 of 12Paloque et al. Malar J  (2016) 15:149 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
plastid (apicoplast) of malaria parasites. Proc Natl Acad Sci USA. 
2013;110:7506–11.
 80. Bhattacharjee S, Stahelin RV, Speicher KD, Speicher DW, Haldar K. 
Endoplasmic reticulum PI(3)P lipid binding targets malaria proteins to 
the host cell. Cell. 2012;148:201–12.
 81. Tawk L, Chicanne G, Dubremetz JF, Richard V, Payrastre B, Vial HJ, et al. 
Phosphatidylinositol 3‑phosphate, an essential lipid in Plasmodium, 
localizes to the food vacuole membrane and the apicoplast. Eukaryot 
Cell. 2010;9:1519–30.
 82. Kobayashi T, Sato S, Takamiya S, Komaki‑Yasuda K, Yano K, Hirata A, et al. 
Mitochondria and apicoplast of Plasmodium falciparum: behaviour 
on subcellular fractionation and the implication. Mitochondrion. 
2007;7:125–32.
 83. Shears MJ, Botte CY, McFadden GI. Fatty acid metabolism in the Plasmo-
dium apicoplast: drugs, doubts and knockouts. Mol Biochem Parasitol. 
2015;199:34–50.
 84. Ralph SA, van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, Foth BJ, 
et al. Tropical infectious diseases: metabolic maps and functions of the 
Plasmodium falciparum apicoplast. Nat Rev Microbiol. 2004;2:203–16.
 85. St Laurent B, Miller B, Burton TA, Amaratunga C, Men S, Sovannaroth S, 
et al. Artemisinin‑resistant Plasmodium falciparum clinical isolates can 
infect diverse mosquito vectors of Southeast Asia and Africa. Nat Com‑
mun. 2015;6:8614.
 86. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemi‑
ology of drug‑resistant malaria. Lancet Infect Dis. 2002;2:209–18.
 87. Witkowski B, Berry A, Benoit‑Vical F. Resistance to antimalarial com‑
pounds: methods and applications. Drug Resist Updat. 2009;12:42–50.
 88. Sanchez CP, Dave A, Stein WD, Lanzer M. Transporters as media‑
tors of drug resistance in Plasmodium falciparum. Int J Parasitol. 
2010;40:1109–18.
 89. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. The ABCs of multidrug 
resistance in malaria. Trends Parasitol. 2010;26:440–6.
 90. Ibraheem ZO, Abd Majid R, Noor SM, Sedik HM, Basir R. Role of different 
Pfcrt and Pfmdr‑1 mutations in conferring resistance to antimalaria 
drugs in Plasmodium falciparum. Malar Res Treat. 2014;2014:950424.
 91. Summers RL, Nash MN, Martin RE. Know your enemy: understanding 
the role of PfCRT in drug resistance could lead to new antimalarial 
tactics. Cell Mol Life Sci. 2012;69:1967–95.
 92. Setthaudom C, Tan‑ariya P, Sitthichot N, Khositnithikul R, Suwandit‑
takul N, Leelayoova S, et al. Role of Plasmodium falciparum chloroquine 
resistance transporter and multidrug resistance 1 genes on in vitro 
chloroquine resistance in isolates of Plasmodium falciparum from 
Thailand. Am J Trop Med Hyg. 2011;85:606–11.
 93. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun 
L, et al. Mefloquine resistance in Plasmodium falciparum and increased 
pfmdr1 gene copy number. Lancet. 2004;364:438–47.
 94. Ubben D, Poll EM. MMV in partnership: the Eurartesim(R) experience. 
Malar J. 2013;12:211.
 95. Ke H, Lewis IA, Morrisey JM, McLean KJ, Ganesan SM, Painter HJ, et al. 
Genetic investigation of tricarboxylic acid metabolism during the 
Plasmodium falciparum life cycle. Cell Rep. 2015;11:164–74.
 96. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1‑Nrf2 
pathway: mechanisms of activation and dysregulation in cancer. Redox 
Biol. 2013;1:45–9.
 97. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada‑Isoe K, Nakashima 
K. PI3K is a key molecule in the Nrf2‑mediated regulation of antioxi‑
dative proteins by hemin in human neuroblastoma cells. FEBS Lett. 
2003;546:181–4.
 98. Raven JF, Koromilas AE. PERK and PKR: old kinases learn new tricks. Cell 
Cycle. 2008;7:1146–50.
 99. Fennell C, Babbitt S, Russo I, Wilkes J, Ranford‑Cartwright L, Goldberg 
DE, et al. PfeIK1, a eukaryotic initiation factor 2alpha kinase of the 
human malaria parasite Plasmodium falciparum, regulates stress‑
response to amino‑acid starvation. Malar J. 2009;8:99.
 100. Zhang M, Mishra S, Sakthivel R, Rojas M, Ranjan R, Sullivan WJ Jr, et al. 
PK4, a eukaryotic initiation factor 2alpha(eIF2alpha) kinase, is essential 
for the development of the erythrocytic cycle of Plasmodium. Proc Natl 
Acad Sci USA. 2012;109:3956–61.
 101. Chaubey S, Grover M, Tatu U. Endoplasmic reticulum stress trig‑
gers gametocytogenesis in the malaria parasite. J Biol Chem. 
2014;289:16662–74.
 102. Doerig C, Endicott J, Chakrabarti D. Cyclin‑dependent kinase homo‑
logues of Plasmodium falciparum. Int J Parasitol. 2002;32:1575–85.
